Pediatric Blood & Cancer

Papers
(The H4-Index of Pediatric Blood & Cancer is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Characterization of COVID‐19 disease in pediatric oncology patients: The New York‐New Jersey regional experience84
COVID‐19 and children with cancer: Parents’ experiences, anxieties and support needs75
Neuroblastoma72
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials51
Ewing sarcoma48
2023 ASPHO Conference Paper and Poster Index47
Clinical presentations and outcomes of children with cancer and COVID‐19: A systematic review47
Impacts of COVID‐19 on caregivers of childhood cancer survivors47
ABSTRACTS41
Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studi38
Late effects of radiation therapy in pediatric patients and survivorship37
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial35
ORAL ABSTRACTS34
Acute lymphoblastic leukemia34
Children and young adults hospitalized for severe COVID‐19 exhibit thrombotic coagulopathy34
Safety of administration of BNT162b2 mRNA (Pfizer‐BioNTech) COVID‐19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG‐asparaginase34
ABSTRACTS33
No increase in psychosocial stress of Dutch children with cancer and their caregivers during the first months of the COVID‐19 pandemic32
Sarcopenia is a prognostic outcome marker in children with high‐risk hepatoblastoma31
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high‐risk neuroblastoma: An International Neuroblastoma Risk Group project30
Homestead together: Pediatric palliative care telehealth support for rural children with cancer during home‐based end‐of‐life care30
Severe adverse events during sirolimus “off‐label” therapy for vascular anomalies29
PediCARE: Development of a poverty‐targeted intervention for pediatric cancer28
A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC‐042)26
Second tumor risk in children treated with proton therapy26
Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years26
0.062356948852539